RX. BioSyent

BioSyent Announces Grant of Restricted Share Units

BioSyent Announces Grant of Restricted Share Units

MISSISSAUGA, Ontario, March 19, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 67,252 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date.   

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 12,731,275 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit .

For further information please contact:

Mr. René C. Goehrum

President and CEO

BioSyent Inc.

E-Mail:

Phone: 905-206-0013

Web:



EN
19/03/2021

Underlying

RX.BioSyent

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioSyent

Free Trial
RX. BIOSYENT

Biosyent Inc: 1 director

Two Directors at Biosyent Inc sold 301,137 shares at between 7.700CAD and 11.450CAD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

9h / 28m 9h / 28m 1 EN
 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent Announces Launch of New FeraMAX® Pd Powder 15

BioSyent Announces Launch of New FeraMAX® Pd Powder 15 MISSISSAUGA, Ontario, Oct. 19, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Powder 15 by its subsidiary, BioSyent Pharma Inc., in Canada. FeraMAX® Pd Powder 15 is the second product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system. In November 2020, BioSyent Pharma Inc. launched FeraMAX® Pd Therapeutic 150, the first product using the PDIC formulation in Canada.    Together, these transitions to the p...

October 19, 2021 1 EN
 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent annonce le lancement du nouveau FeraMAX (MD) Pd Poudre 15

BioSyent annonce le lancement du nouveau FeraMAX (MD) Pd Poudre 15 MISSISSAUGA, Ontario, 19 oct. 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent »,« la Société », Bourse de croissance TSX : RX) a le plaisir d’annoncer le lancement de FeraMAXMD Pd Poudre 15 par sa filiale, BioSyent Pharma Inc, au Canada. FeraMAXMD Pd Poudre 15 est le deuxième produit intégrant le complexe polydextrose-fer (CPDF), un système breveté de supplémentation en fer par voie orale. En novembre 2020, BioSyent Pharma Inc. a lancé FeraMAXMD Pd Thérapeutique 150, le premier produit utilisant la formulation CPDF au C...

October 19, 2021 1 EN
 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent Releases Q2 and H1 2021 Financial Results

BioSyent Releases Q2 and H1 2021 Financial Results MISSISSAUGA, Ontario, Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021. Key highlights include: Second quarter (Q2) 2021 Net Revenues of $7,289,254 increased by 53% versus Q2 2020First half (H1) 2021 Net Revenues of $14,709,143 increased by 36% versus H1 2020Record quarterly Canadian Pharmaceutical Net Revenues in Q2 2021 of $6,670,322 increased by 51% versus Q2 2020H1 2021 Canadian Pharmaceutical Net Revenues of $12,904,085...

August 25, 2021 1 EN
 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent Signs Exclusive Technology Agreement

BioSyent Signs Exclusive Technology Agreement MISSISSAUGA, Ontario, July 13, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent’s international markets. “As a market leader in the treatment and prevention of iron deficiency and iron deficiency anemia with our FeraMAX® brand, we are familiar with the challenges that patients and their healt...

July 13, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch